Platelet survival studies. An overview of the factors affecting the efficiency and reliability of platelet radiolabeling

Transfusion ◽  
1986 ◽  
Vol 26 (1) ◽  
pp. 19-22 ◽  
Author(s):  
JG Kelton
1975 ◽  
Vol 34 (01) ◽  
pp. 050-062
Author(s):  
Dale H Cowan ◽  
Richard C Graham ◽  
Patricia Shook ◽  
Ronda Griffin

SummaryTo determine the effect on platelet behavior of transient exposure of platelets to ascorbic acid, studies of platelet function and ultrastructure were done before exposure to ascorbic acid at pH 6.5, during exposure to pH 6.5, and after restoration of pH to pre-acidifìcation levels. The effect of ascorbic acid (A. A.) was compared to that of HCl and citric acid (C. A.). ADP- and collagen-induced aggregation of normal platelets were significantly impaired by both A. A. and C. A. but were less affected by HCl. The release of 14C-serotonin was significantly reduced by each agent. The ultra-structure of normal platelets brought to pH 6.5 by A.A. was normal. After neutralization, there was marked dilatation of the open channel system and loss of the disc shape. When platelets were brought to pH 6.5 by A. A., then neutralized, the aggregates which formed after stimulation by ADP or collagen were smaller than normal, the platelets were less closely approximated, and degranulation was less complete. The data show that exposure of platelets to ascorbic acid for short intervals impairs their function when measured after restoration of pH to levels compatible with maximal responses. Platelet survival studies using autologous platelets labelled with 51Cr in the presence or absence of ascorbic acid showed that the recovery of normal platelets was unaffected by ascorbic acid, whereas recovery of platelets from patients with idiopathic thrombocytopenic purpura, idiopathic thrombocythemia, and alcohol-related thrombocytopenia was markedly reduced. The injury resulting from the use of ascorbic acid in preparing platelets for studies of platelet survival in patients with disorders affecting platelets may impair the recovery of the cells, resulting in artifactual changes in the survival studies.


1982 ◽  
Vol 11 (2) ◽  
pp. 102-108
Author(s):  
Fabrizio Fabris ◽  
Alessandra Casonato ◽  
Maria Luigia Randi ◽  
Lucia Varotto ◽  
Cesare Scandellari ◽  
...  

1972 ◽  
Vol 23 (11) ◽  
pp. 513-517 ◽  
Author(s):  
R.D. Smith ◽  
J.J.B. Anderson ◽  
Miodrag Ristic ◽  
D.L. Huxsoll

Transfusion ◽  
1986 ◽  
Vol 26 (1) ◽  
pp. 37-42 ◽  
Author(s):  
EL Snyder ◽  
G Moroff ◽  
T Simon ◽  
A Heaton

1991 ◽  
Vol 78 (2) ◽  
pp. 236-241 ◽  
Author(s):  
R. A. de Vries ◽  
M. de Bruin ◽  
S. J. Oldenburg ◽  
A. Zwiers ◽  
J. J. M. Marx ◽  
...  

Blood ◽  
1981 ◽  
Vol 58 (3) ◽  
pp. 444-450
Author(s):  
TJ Myers ◽  
BK Kim ◽  
M Steiner ◽  
MG Baldini

A quantitative immunofluorescence platelet-associated immunoglobulins (PA-IgG) assay was used to detect alloimmunity to platelets in 8/12 multitransfused patients and to perform platelet crossmatching in the 8 alloimmunized patients. The correct separation of multitransfused patients into alloimmune and nonalloimmune groups was substantiated with chromium-51-labeled platelet survival studies. For 5 alloimmunized patients, compatible and incompatible donor platelets were demonstrated by PA-IgG crossmatching and were confirmed by platelet survival studies. With the other 3 alloimmunized patients, only studies with 5 of these incompatible donor platelets showed markedly reduced survival times on 4 occasions. PA-Igg compatible donor platelets survived 3.5- 8.7 days, while PA-IgG incompatible platelets showed survival times of 0.1–2.4 days. Overall, PA-IgG testing correctly indicated survival results on 15/17 occasions (88%), whereas platelet aggregation, serotonin release, and lymphocytotoxicity testing showed correct predictions for only 41%-59% of the survival studies. PA-IgG testing predicted which times, thus indication patients with platelet-specific alloantibodies. the PA-IgG assay provides a sensitive method to detect platelet alloantibodies and to perform platelet crossmatching, which can complement HLA typing in the selection of donor platelets for alloimmunized patients.


Sign in / Sign up

Export Citation Format

Share Document